<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202653</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-A3334-II-02</org_study_id>
    <nct_id>NCT04202653</nct_id>
  </id_info>
  <brief_title>Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)</brief_title>
  <acronym>Neptune</acronym>
  <official_title>New Combination of ETV, TQ-A3334 and TQ-B2450 for the Treatment of Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to
      evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of
      TQ-B2450 versus ETV alone in chronic hepatitis B patients. Patients were randomized to one of
      3 different antiviral treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HBsAg quantification at week 24</measure>
    <time_frame>week 24</time_frame>
    <description>HBsAg quantification are measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rates at week 24</measure>
    <time_frame>week 24</time_frame>
    <description>HBsAg loss rates are measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg seroconversion rates at week 24</measure>
    <time_frame>week 24</time_frame>
    <description>HBsAg seroconversion rates are measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss rates at week 24</measure>
    <time_frame>week 24</time_frame>
    <description>HBeAg loss rates are measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion rates at week 24</measure>
    <time_frame>week 24</time_frame>
    <description>HBeAg seroconversion rates are measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA&lt;20IU/mL rates at week 24</measure>
    <time_frame>week 24</time_frame>
    <description>HBV DNA&lt;20IU/mL rates are measured</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Naive:ETV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Entecavir 0.5 mg po daily for 24 weeks in naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naive:ETV+TQ-A3334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naive:ETV+TQ-A3334+TQ-B2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir 0.5 mg po daily plus TQ-A3334 plus inhibitor of TQ-B2450 for 24 weeks in naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experienced:ETV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Entecavir 0.5 mg po daily for 24 weeks in treatment experienced patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experienced:ETV+TQ-A3334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir 0.5 mg po daily plus TQ-A3334 for 24 weeks in treatment experienced patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experienced:ETV+TQ-A3334+TQ-B2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir 0.5 mg po daily plus TQ-A3334 plus TQ-B2450 for 24 weeks in treatment experienced patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETV</intervention_name>
    <description>entecavir 0.5 mg qd</description>
    <arm_group_label>Experienced:ETV</arm_group_label>
    <arm_group_label>Experienced:ETV+TQ-A3334</arm_group_label>
    <arm_group_label>Experienced:ETV+TQ-A3334+TQ-B2450</arm_group_label>
    <arm_group_label>Naive:ETV</arm_group_label>
    <arm_group_label>Naive:ETV+TQ-A3334</arm_group_label>
    <arm_group_label>Naive:ETV+TQ-A3334+TQ-B2450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-A3334</intervention_name>
    <description>TQ-A3334 po qw</description>
    <arm_group_label>Experienced:ETV+TQ-A3334</arm_group_label>
    <arm_group_label>Experienced:ETV+TQ-A3334+TQ-B2450</arm_group_label>
    <arm_group_label>Naive:ETV+TQ-A3334</arm_group_label>
    <arm_group_label>Naive:ETV+TQ-A3334+TQ-B2450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B2450</intervention_name>
    <description>TQ-B2450 q3w iv</description>
    <arm_group_label>Experienced:ETV+TQ-A3334+TQ-B2450</arm_group_label>
    <arm_group_label>Naive:ETV+TQ-A3334+TQ-B2450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients from 18 to 65 years of age;

          2. Chronic hepatitis B infection

          3. Negative urine or serum pregnancy test (for women of childbearing potential)
             documented within the 24-hour period prior to the first dose of test drug;

          4. Agree to participate in the study and sign the patient informed consent.

        Exclusion Criteria:

          1. Patients who had NAs resistance;

          2. Other antiviral, anti-neoplastic or immunomodulatory treatment;

          3. Women with ongoing pregnancy or breast-feeding;

          4. Co-infection with active hepatitis A, hepatitis C, hepatitis D(Those hospitals which
             have the ability to do the test will do) and/or human immunodeficiency virus (HIV);

          5. ALT &gt;10 ULN;

          6. LSM &gt;9kPa ;

          7. History or other evidence of a medical condition associated with chronic liver disease
             other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic
             liver disease, alcoholic liver disease, toxin exposures, thalassemia);

          8. Signs or symptoms of hepatocellular carcinoma;

          9. Neutrophil count &lt; 1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening;

         10. Hemoglobin &lt; 11.5 g/dL for females and &lt;12.5 g/dL for men;

         11. Serum creatinine level &gt; 1.5 ULN in screening period.

         12. Phosphorus &lt; 0.65 mmol/L;

         13. ANA &gt; 1:100;

         14. History of severe psychiatric disease;

         15. History of a severe seizure disorder or current anticonvulsant use;

         16. History of immunologically mediated disease, (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia,
             scleroderma, rheumatoid arthritis etc.);

         17. History of chronic pulmonary disease associated with functional limitation;

         18. Diseases that IFN and Nucleotides or nucleosides are not suitable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Qin Ning</investigator_full_name>
    <investigator_title>Director, Head of Department of Infectious Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

